Summary

Buyer: Roche Holding Ltd. (ADR) (RHHBY) Last Price: 89.90 Market Cap.: 155.09B
Target: Protherics PLC (ADR) (PTIL) Last Price: 14.24 Market Cap.: 3.45B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 866
Biopharmaceuticals 322
Medical Devices   245
Scientific Products   42
Veterinary Products and Services   7

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 230)
  • Xolair (Omalizumab)
  • Cardene (Nicardipine Hydrochloride)
  • Dilatrend (Carvedilol)
  • Demadex (Torsemide)
Target (Total: 7)
  • Angiotensin Vaccine
  • CytoFab
  • Prolarix
  • CroFab [(Crotalidae Polyvalent Immune Fab (Ovine)]
Buyer
  • Roche Diagnostics AVL Compact 1-3
  • Roche Diagnostics OMNI Series
  • Roche Diagnostics AVL 988 Series
  • Roche Diagnostics AVL 9180 Series
Target
  • Protherics Enfer TSE Diagnostic Kit

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 44)
  • Aspreva Pharmaceuticals Corporation (ASPV)
  • Emisphere Technologies Inc. (EMIS)
  • deCODE genetics, Inc. (DCGN)
  • PDL BioPharma Inc. (PDLI)
Target (Total: 1)
  • Symbion Health Limited (SYHTY)
Buyer (Total: 13)
  • Applied Biosystems Group, Applera Corp (ABI)
  • IDEXX Laboratories, Inc. (IDXX)
  • MDS Inc. (USA) (MDZ)
  • Gen-Probe Incorporated (GPRO)
Target (Total: 0)

n/a

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 68,218 214
Revenue Per Employee 470,734.5 125,374.4
Total Revenue 15,973.8 13.2
Total Expenses 11,302.1 24.4
Other Revenue 0.0 0.0
Cost of Revenue 3,970.7 6.8
SG&A Expense 5,053.9 9.3
Research & Development 2,465.0 8.2
Other Operating Expense -585.1 0.0
Operating Income 4,671.7 -11.2
Unusual Income 0.0 0.0
LT Debt to Capital 18.78 12.91
Fwd P/E 24.03 n/a
Fwd P/Rev 5.11 n/a
Book Value 27,912.4 49.5
Curr Portion of LTD/Cap Lease 276.8 1.2

Key Ratios

  Buyer Target
Gross Margin % 73.8 36.24
Operating Margin % 24.41 -53.83
Quick Ratio 3.01 1.83
Current Ratio 3.75 2.47
Coverage Ratio 0.03 0
Total Assets 54,020.5 113.0
Return on Equity % 19.31 -36
Return on Assets % 9.72 -15.78
Cash+ ST Inv. Per Share 9.46 1.91
Total Debt 7,530.9 8.6
Total Debt to Equity % 27.69 17.33
Total Debt to Tangible Equity % 42.91 28.38
Debt to Asset % 13.94 7.59

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Roche Holding Ltd. is in the business of pharmaceuticals and diagnostics. Its pharmaceutical division offers a portfolio of medicines in various therapeutic areas, including cancer, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), hepatitis C, transplantation, dermatology and influenza. The Company's diagnostic division supplies an array of testing products and services to researchers, physicians, patients, hospitals and laboratories worldwide. Its products and services address prevention, diagnosis, treatment and the monitoring of diseases. The Company has operations in approximately 150 countries. During the year ended December 31, 2004, the Company has 64 new molecular entities in the research and development pipeline. In 2004, the Company's first deoxyribonucleic acid (DNA) chip-based test introduced to support more personalized therapy.

Target

Protherics PLC is a biopharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products for the treatment of human diseases. The Company's core technology is focused on immunotherapeutics and oncology. Immunotherapeutics encompasses the use of antibodies to combat the effects of disease or poisoning. Protherics PLC has manufacturing facilities in Wales, Australia and Salt Lake City, Utah. On December 7, 2005, the Company licensed CytoFab, its product developed for the treatment of sepsis, to AstraZeneca Ireland Operations, a branch in Ireland of AstraZeneca UK Limited (AstraZeneca).

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
  
Medical Devices  
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Scientific Products  
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of biochemical samples.
  
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
  
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
  
General Laboratory Equipment
The General Laboratory Equipment Subsector includes products that are used during routine laboratory procedures, such as sample preparation, processing, storage, cleaning, and purification.
  
Veterinary Products and Services  
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.

Target Products:

  • Protherics Enfer TSE Diagnostic Kit
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.

Buyer Products:

  • Xolair (Omalizumab)
  
Upper Respiratory  
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.

Buyer Products:

  • Xolair (Omalizumab)
  
Cardiovascular System
Heart Disorders  
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Cardene (Nicardipine Hydrochloride)
  
Heart Failure (HF)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Dilatrend (Carvedilol)
  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Demadex (Torsemide)
  • Bumex (Bumetanide)
  
Myocardial Infarction (MI)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Dilatrend (Carvedilol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • BO-653 (Antioxidant)
  • TF Fab (Monoclonal Antibody Fragment)
  • R639/SPP301 (Endothelin Receptor A Antagonist)
  • AXV034343 (Endothelin A Receptor Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Target Products:

  • Angiotensin Vaccine
  
Vascular Disorders  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat/prevent thrombosis by selectively inhibiting the binding of adenosine diphosphate (ADP) to its platelet receptor, thereby inhibiting platelet aggregation.

Buyer Products:

  • Ticlid (Ticlopidine Hydrochloride)
  
Hypertension  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Cardene (Nicardipine Hydrochloride)
  • Cardene SR (Nicardipine Hydrochloride)
  
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Demadex (Torsemide)
  
Stroke  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.

Buyer Products:

  • Ticlid (Ticlopidine Hydrochloride)
  
Dermatology  
Acne  
Vulgaris  
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.

Buyer Products:

  • Roaccutane/Accutane (Isotretinoin)
  
Lesion/Scaling Disorders  
Psoriasis  
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Raptiva (Efalizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • BAL4079 (9-Cis Retinoic Acid)
  • BAL2299 (Nuclear Receptor Modulator)
  • BCX-4208 (Second-Generation PNP Inhibitor)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Kytril (Granisetron Hydrochloride)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Bumex (Bumetanide)
  • Demadex (Torsemide)
  
Hepatitis  
Hepatitis B  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  
Hepatitis C  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections by preventing viral replication, stimulating the immune system to also fight the virus, and inhibits replication of viral DNA by incorporating themselves into growing viral DNA stands.

Buyer Products:

  • Pegasys/Copegus (Pegylated Interferon Alfa-2a/Ribavirin)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1518 (Levovirin)
  • R440 (Cell Cycle Inhibitor)
  • GM -611 (Motilin Agonist)
  • R1124 (GPCR Modulator)
  • R1270 (Levovirin)
  • R1479 (Polymerase Inhibitor)
  • R1068 (GPCR Modulator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1541 (Integrin Antagonist)
  • R1626 (Polymerase Inhibitor)
  
Endocrinology/Metabolism  
Diabetes  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitizes organs to insulin.

Buyer Products:

  • R483 (Insulin Sensitizer)
  
Intermediary Metabolism Disorders  
Gout  
Gouty Arthritis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Parathyroid Gland Disorders  
Hyperparathyroidism (HPT)  
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.

Buyer Products:

  • Rocaltrol (Calcitriol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1439 (Nuclear Receptor Modulator)
  • R1440 (Enzyme Modulator)
  • R1438 (Enzyme Inhibitor)
  • BIM 51077 (GLP-1 Analogue)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1499 (Enzyme Inhibitor)
  • R1593 (Nuclear Receptor Modulator)
  • Glucokinase Enzyme
  • R1498 (Nuclear Receptor Modulator)
  
Hematology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1516
  • Mircera/CERA (Continuous Erythropoietin Receptor Activator)
  
Red Blood Cell (RBC) Disorders  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.

Buyer Products:

  • NeoRecormon (Epoetin Beta)
  • Mircera/CERA (Continuous Erythropoietin Receptor Activator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1593 (Nuclear Receptor Modulator)
  
Serum Factor Disorders  
Hypocalcemia  
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.

Buyer Products:

  • Rocaltrol (Calcitriol)
  
Immunology  
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Immunotherapy  
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Rituxan (Rituximab)
  • R1569/MRA (Tocilizumab)
  
Psoriasis  
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Raptiva (Efalizumab)
  
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.

Buyer Products:

  • Fuzeon (Enfuvirtide)
  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Hivid (Zalcitabine)
  
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.

Buyer Products:

  • Fortovase (Saquinivir)
  • Invirase (Saquinavir Mesylate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1295 (Integrin Antagonist)
  • Fortovase (Saquinivir)
  • R1594 (Anti-CD20 Molecule )
  • R1599
  • BAL2299 (Nuclear Receptor Modulator)
  • R1487 (Kinase Inhibitor)
  • R724/T-1249 (Fusion Inhibitor)
  • R944 (Protease Inhibitor)
  • Raptiva (Efalizumab)
  • R1503 (Kinase Inhibitor)
  • BCX-4208 (Second-Generation PNP Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1541 (Integrin Antagonist)
  • R1628
  • R1495 (Non-Nucleoside Reverse Transcriptase Inhibitor)
  • BCX-4208 (Second-Generation PNP Inhibitor)
  • BR3-FC
  • CLIP (Class II Associated Invariant Chain Peptide)
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Rocephin (Ceftriaxone Sodium)
  
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.

Buyer Products:

  • Gantrisin (Sulfisoxazole)
  
Narrow Spectrum  
Digestive System  
Shigellosis  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat an infection of the intestines caused by Shigella by inhibiting folic acid synthesis.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Otolaryngology (Ear/Nose/Throat)  
Otitis Media  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Respiratory System  
Bronchitis  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Mycological (Fungal)  
Antifungal Agents  
Narrow Spectrum  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors/Dihydropteroate Synthetase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by interfering with folic acid synthesis and growth of organism.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • R944 (Protease Inhibitor)
  • R724/T-1249 (Fusion Inhibitor)
  • R1270 (Levovirin)
  • Fortovase (Saquinivir)
  • BAL8557 (Antifungal Agent)
  • BAL5788 (Antibiotic)
  • R1558
  • CS-023 (Prenteral Crbapenem)
  • R1461 (Fusion Protein)
  • R1479 (Polymerase Inhibitor)
  • R1518 (Levovirin)

Target Products:

  • CytoFab
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.

Buyer Products:

  • Lariam (Mefloquine Hydrochloride)
  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat infections due to parasites by inhibiting folic acid synthesis and also blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Fansidar (Sulfadoxine/Pyrimethamine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • R1495 (Non-Nucleoside Reverse Transcriptase Inhibitor)
  • BAL8349 (Antifungal Agent)
  • Tamiflu (Oseltamivir)
  • R1626 (Polymerase Inhibitor)
  
Viral  
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  
Herpesvirus  
Cytomegalovirus (CMV)  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Valcyte (Valganciclovir Hydrochloride)
  
RNA Viruses  
Flavivirus  
Hepatitis C  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections characterized by long term inflammation of the liver by enhancing the immune system and by inhibiting replication of viral DNA.

Buyer Products:

  • Pegasys/Copegus (Pegylated Interferon Alfa-2a/Ribavirin)
  
Orthomyxovirus  
Influenza A  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Influenza B  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.

Buyer Products:

  • Fuzeon (Enfuvirtide)
  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Hivid (Zalcitabine)
  
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.

Buyer Products:

  • Invirase (Saquinavir Mesylate)
  • Fortovase (Saquinivir)
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1599
  • R1164
  • R1295 (Integrin Antagonist)
  • R1487 (Kinase Inhibitor)
  • Raptiva (Efalizumab)
  • Rituxan (Rituximab)
  • R1503 (Kinase Inhibitor)
  • CHS 13340 (Recombinant Parathyroid Hormone)
  • ED-71 (Vitamin D Derivative)
  • R1594 (Anti-CD20 Molecule )
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1628
  • BR3-FC
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.

Buyer Products:

  • Boniva (Ibandronate Biphosphonate)
  
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.

Buyer Products:

  • Evista (Raloxifene Hydrochloride)
  
Joint Disorders  
Ankylosing Spondylitis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Gouty Arthritis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Osteoarthritis (OA)  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Immunotherapy  
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • R1569/MRA (Tocilizumab)
  • Rituxan (Rituximab)
  
Neurology  
Neurological Disorders  
Epilepsy  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Akinetic Pattern  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Myoclonic  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MT 500 (GPCR Modulator)
  • R1204 (GPCR Modulator)
  • R673 (GPCR Modulator)
  • Rituxan (Rituximab)
  
Psychiatric Disorders  
Anxiety  
Generalized Anxiety Disorder (GAD)  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Valium (Diazepam)
  
Panic Disorder  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Klonopin (Clonazepam)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1067 (GPCR Modulator)
  • R641
  • R1576 (GPCR Modulator)
  • R1450
  
Oncology
Breast Cancer  
Localized  
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  • Herceptin (Trastuzumab)
  
Metastatic  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.

Buyer Products:

  • Xeloda (Capecitabine)
  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.

Buyer Products:

  • Herceptin (Trastuzumab)
  • Avastin (Bevacizumab)
  
Dermatology  
Kaposi`s Sarcoma  
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Metastatic  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal tumors that have spread beyond their original tumor site by inhibiting the production of DNA.

Buyer Products:

  • Xeloda (Capecitabine)
  
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Pancreatic Cancer  
Metastatic  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Buyer Products:

  • Tarceva (Erlotinib)
  
Hematology  
Leukemia  
Lymphoid  
Chronic  
Hairy Cell  
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.

Buyer Products:

  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Lymphocytic (CLL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.

Buyer Products:

  • Rituxan (Rituximab)
  
Myeloid  
Acute  
Promyelocytic (APL)  
Retinoids/Vitamin A Analogs
Therapeutics that treat acute promyelocytic leukemia by helping in cell differentiation as well as decreasing proliferation of cells.

Buyer Products:

  • Vesanoid (Tretinoin)
  
Chronic  
Myelogenous (CML)  
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Lymphoma  
Non-Hodgkin`s Lymphoma (NHL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.

Buyer Products:

  • Rituxan (Rituximab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • KOS-862 (Epothilone D)
  • R1564/DMXAA (Vascular Targeting Agent)
  • Trastuzumab-DM1
  • Tarceva (Erlotinib)
  • Therex
  • Therafab
  • Pemtumomab/R1549
  • Diflomotecan (Topoisomerase Inhibitor I)
  • R1492 (Enzyme Inhibitor)
  • R1594 (Anti-CD20 Molecule )
  • E2F Activating Compound
  • R1668 (E2F Modulator)
  • AS1404
  • PRO64553 (Anti-CD40 Antibody)
  • Avastin (Bevacizumab)
  • R1273 (Monoclonal Antibody)
  • CAL (Anti-PTHrP Monoclonal Antibody)
  • CHC 12103 (Polyglutamate TXL)
  • AHM (Anti-HM 1.24 Monoclonal Antibody)
  • R1536 (Enzyme Inhibitor)
  • R1550 (Monoclonal Antibody)

Target Products:

  • Prolarix
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • R547 (Enzyme Inhibitor)
  • BN80927 (Topoisomerase I/II Inhibitor)
  • R1630 (Enzyme Inhibitor)
  • R1645 (Enzyme Inhibitor)
  • R1491 (Angiogenesis Inhibitor)
  • PRO1762
  • R1453 (Enzyme Inhibitor)
  • P53 Pathway Activators
  • 2H7
  • R1559 (Enzyme Inhibitor)
  • R1454 (Enzyme Inhibitor)
  
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.

Buyer Products:

  • Tarceva (Erlotinib)
  
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Urology  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Ovarian Cancer  
Adenocarcinoma  
Monoclonal Antibodies
Therapeutics that treat ovarian cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Pemtumomab/R1549
  
Ophthalmology  
Degenerative Disorders  
Macular Degeneration (AMD)  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Retinitis  
AIDS-Related Cytomegalovirus (CMV) Retinitis  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Valcyte (Valganciclovir Hydrochloride)
  • Cytovene (Ganciclovir)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Versed (Midazolam)
  
Reversal  
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.

Buyer Products:

  • Romazicon (Flumazenil)
  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  • Toradol (Ketorolac Tromethamine)
  • Aleve (Naproxen Sodium)
  
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.

Buyer Products:

  • Aleve Cold & Sinus (Naproxen/Pseudoephedrine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Buyer Products:

  • Bondronat (Ibandronate)
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Prophylactic Treatments  
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.

Buyer Products:

  • Xolair (Omalizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R411 (Integrin Antagonist)
  • R1295 (Integrin Antagonist)
  • R667 (Nuclear Receptor)
  • Zenapax (Daclizumab)
  • R448
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1456 (Nuclear Receptor)
  
Surgery  
Cardiovascular System  
Complications  
Peripheral Arterial Occlusion  
Thrombolytic Agents
Therapeutics that treat diseases of the blood vessels outside the heart by dissolving blood clots.

Buyer Products:

  • Cathflo Activase (Alteplase)
  
Toxicology
Animal Poisoning  
Snakes  
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.

Target Products:

  • CroFab [(Crotalidae Polyvalent Immune Fab (Ovine)]
  
Chemical Poisoning  
Digoxin  
Digoxin Binding Agents
Therapeutics that treat toxicity due to ingestion of excessive digoxin by competitively binding to digoxin, making them unavailable for binding at their site of action on cells in the body.

Target Products:

  • DigiFab [Digoxin Immune Fab (Ovine)]
  
Methotrexate  
Carboxypeptidase
Therapeutics that treat methotrexate toxicity by catalyzing its carboxyl groups.

Target Products:

  • Voraxaze
  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Buyer Products:

  • Valium (Diazepam)
  
Transplantation  
Bone Marrow  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  
Heart  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • CellCept (Mycophenolate Mofetil)
  
Hepatic (Liver)  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Valcyte (Valganciclovir Hydrochloride)
  • Cytovene (Ganciclovir)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • CellCept (Mycophenolate Mofetil)
  
Lung  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Pancreas  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Valcyte (Valganciclovir Hydrochloride)
  • Cytovene (Ganciclovir)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.

Buyer Products:

  • BCX-4208 (Second-Generation PNP Inhibitor)
  • Raptiva (Efalizumab)
  • VAL (Liver Regenerator)
  • R1524 (Calcineurin Inhibitor)
  • ISATX247 Trans
  
Renal (Kidney)  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Valcyte (Valganciclovir Hydrochloride)
  • Cytovene (Ganciclovir)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • CellCept (Mycophenolate Mofetil)
  
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.

Buyer Products:

  • Zenapax (Daclizumab)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1484 (GPCR Modulator)
  • R701 (GPCR Antagonist)
  • R450 (GPCR Modulator)
  • Mircera/CERA (Continuous Erythropoietin Receptor Activator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1554 (GPCR Antagonist)
  • R873 (GPCR Agonist)
  • R1437 (GPCR Antagonist)
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.

Buyer Products:

  • Mircera/CERA (Continuous Erythropoietin Receptor Activator)
  
Edema  
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.

Buyer Products:

  • Bumex (Bumetanide)
  • Demadex (Torsemide)
  
Weight Management  
Obesity  
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.

Buyer Products:

  • Xenical (Orlistat)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1065 (GPCR Modulator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1496 (GPCR Modulator)
  
Wound Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.

Buyer Products:

  • Vascular Endothelial Growth Factor
  
Medical Devices  
Clinical Diagnostics  
Chemistry  
Analyzers  
Blood Gas
Analyzers used to measure blood gases for diagnostic purposes.

Buyer Products:

  • Roche Diagnostics AVL Compact 1-3
  • Roche Diagnostics OMNI Series
  • Roche Diagnostics AVL 988 Series
  
Discrete  
Limited Assay
Discrete analyzers with limited test menu.

Buyer Products:

  • Roche Diagnostics OMNI Series
  • Roche Diagnostics AVL 9180 Series
  
Multiple Assay
Multi-System analyzers designed for high throughput generally used in high volume clinical laboratories.

Buyer Products:

  • Roche Diagnostics Cobas Integra Series
  • Roche Diagnostics Roche/Hitachi 902/912
  • Roche Diagnostics Reflotron Series
  
Home Testing  
Cholesterol
Home test kits which test for cholesterol levels in patient blood.

Buyer Products:

  • Roche Diagnostics Accu-Chek Plus
  • Roche Diagnostics Accutrend System
  
Glucose  
Invasive
Devices that generally use blood samples for testing and require a needlestick or pin-prick.

Buyer Products:

  • Roche Diagnostics Accu-Chek Active Meter
  • Roche Diagnostics Accu-Chek Advantage/Advantage II/Sensor Meter
  • Roche Diagnostics Accu-Chek Complete/Sensor Complete Meter
  • Roche Diagnostics Accu-Chek Aviva
  • Roche Diagnostics Accu-Chek Plus
  • Roche Diagnostics Accu-Chek Simplicity
  • Roche Diagnostics Accu-Chek Instant DM
  • Roche Diagnostics Accu-Chek Compact Meter
  
Test Strips
Specific glucose test devices used with glucose monitors.

Buyer Products:

  • Roche Diagnostics Accu-Chek Advantage Test Strips
  • Roche Diagnostics Accu-Chek Active Test Strips
  • Roche Diagnostics Glucotrend Strips
  • Roche Diagnostics Accu-Chek Simplicity Test Strips
  • Roche Diagnostics Accu-Chek Compact Test Drums
  • Roche Diagnostics Accu-Chek Comfort Curve/Sensor Comfort/Advantage Comfort/Advantage II Test Strips
  • Roche Diagnostics Accu-Chek Go
  
Point of Care Testing  
Critical Care Analysis  
Analyzers
Chemistry analyzers which may be used for the chemical analysis of body fluids and designed for use at the bedside during the course of patient care.

Buyer Products:

  • Roche Diagnostics Elecsys 2010
  • Roche Diagnostics Elecsys 1010
  
Test Cartridges
Specific analyte test devices used in conjunction with critical care chemistry analyzers.

Buyer Products:

  • Roche Diagnostics Elecsys 2010
  • Roche Diagnostics Elecsys 1010
  
Glucose Monitoring  
Invasive  
Continuous Analysis
Glucose test devices which measure patient glucose levels on a continual basis.

Buyer Products:

  • GlucOnline Microdialysis System
  
Random Analysis
Glucose test devices which measure patient glucose levels as a blood sample is obtained.

Buyer Products:

  • Roche Diagnostics AccuData GTS/AccuData HDM
  • Roche Diagnostics Accu-Chek Inform System
  
Kits  
Cardiac
Test kits used to aid in the diagnosis of heart conditions.

Buyer Products:

  • Roche Diagnostics Cardiac D-Dimer
  
Reagents  
Calibrators  
Routine Analyte  
Multiple
Calibrators which contain multiple specific analytes used to establish the accuracy of chemistry analyzers.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Single
Calibrators which contain a specific analyte used to establish the accuracy of chemistry analyzers.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Controls  
Routine
Controls used to test the accuracy of discrete chemistry test systems.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Test Kits  
Pharmacogenetic
Test kits designed to determine individuals' reaction to specific medications based on their specific genes.

Buyer Products:

  • Roche Diagnostics AmpliChip CYP450 Test
  
Hemostasis/Coagulation  
Analyzers  
Automated
Automated coagulation analyzers.

Buyer Products:

  • Roche Diagnostics Stago Sta Compact
  • Roche Diagnostics Stago Sta R
  
Reagents  
Test Kits  
Prothrombin Time
Reagents used to perform prothrombin time assays.

Buyer Products:

  • Roche Diagnostics CoaguChek Series
  
Immunoassays  
Analyzers  
Autoimmune
Analyzers used to perform autoimmune testing.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR Analyser
  • Roche Diagnostics COBAS AmpliPrep System
  
Multiple Assay
Immunoassay analyzer designed to perform multiple assays over multiple modalities.

Buyer Products:

  • Roche Diagnostics Elecsys 1010
  • Roche Diagnostics Cobas Core II
  • Roche Diagnostics E170
  • Roche Diagnostics Elecsys 2010
  
Reagents  
Calibrators  
Therapeutic Drugs
Calibrators used in the measurement of therapeutic drugs.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Toxicology/Abuse Drugs
Calibrators used in the measurement of drugs of abuse.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Controls  
Therapeutic Drugs
Controls which contain known concentrations of specific therapeutic drugs used to verify the performance of therapeutic drug testing systems.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Test Kits  
Bacterial  
Chlamydia
Immunoassay kits which test for current or previous infection caused by the Chlamydia organism.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR CT/NG Test/AMPLICOR CT/NG Test
  
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.

Buyer Products:

  • Roche Diagnostics Amplicor M. tuberculosis Test
  
Radioimmunoassays  
Cancer Marker
Radioimmunoassay test kits which measure for cancer markers in plasma or serum.

Buyer Products:

  • Roche Diagnostics Cobas Core Reagent Series
  
Cardiac
Radioimmunoassay test kits which measure for analytes associated with heart disease in plasma or serum.

Buyer Products:

  • NT-proBNP
  
Special/Immuno Chemistry  
Cancer Marker  
Breast
Diagnostic assay used to detect specific breast tumor or cancer markers.

Buyer Products:

  • BCM 18 (Breast Cancer Marker)
  
Colorectal (Colon)
Diagnostic assay used to detect specific colorectal (colon) tumor or cancer markers.

Buyer Products:

  • Roche Diagnostics hemo FEC
  
Cardiac  
Myocardial Infarction/Heart Failure  
Myoglobin
Immunoassay test kits which quantitatively measure for myoglobin in plasma or serum.

Buyer Products:

  • Roche Diagnostics Cardiac Reader
  
Troponin
Immunoassay test kits which quantitatively measure for troponin in plasma or serum.

Buyer Products:

  • Roche Diagnostics Cardiac Reader
  • Roche Diagnostics TROPT Sensitive
  
Therapeutic Drugs
Immunoassay test kits which quantitatively measure for therapeutic drugs in serum or urine using automated instrumentation..

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Toxicology/Abuse Drugs  
Multiple Drug Kit
Immunoassay test kits which measure for more than one drug of abuse in body fluids.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  • Roche Diagnostics OnTrak TesTcard 9
  
Viral  
Human Immunodeficiency Virus (HIV)  
Serum  
Genotyping
Tests that "fingerprint" HIV according to chromosomal makeup in order to track specific strains.

Buyer Products:

  • Roche Diagnostics COBAS Amplicor HIV-1 Test
  • Roche Diagnostics AMPLICOR HIV-1 Monitor Test
  • Roche Diagnostics Amplicor HIV-1 Test
  
Microbiology  
Genetic Probes/PCR  
Reagents  
Bacterial  
Tuberculosis
Genetic probe for detection and/or quantitation of Mycobacterium tuberculosis.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR MTB Test/AMPLICOR MTB Test
  • Roche Diagnostics COBAS AMPLICOR Mycobacterium avium Test/AMPLICOR MAV Test
  • Roche Diagnostics COBAS AMPLICOR Mycobacterium Intracellular (MIN) Test/AMPLICOR MIN Test
  
Viral  
Cytomegalovirus
Genetic probe for detection and/or quantitation of Cytomegalovirus.

Buyer Products:

  • Roche Diagnostics AMPLICOR CMV Test
  • Roche Diagnostics COBAS AMPLICOR CMV Monitor Test
  
Hepatitis B Virus
Genetic probes for detection and/or quantitation of HBV.

Buyer Products:

  • Roche Diagnostics AMPLINAT MPX Test
  • Roche Diagnostics COBAS AmpliScreen HBV Test
  
Hepatitis C Virus
Genetic probes for detection and/or quantitation of HCV.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR HCV Monitor Test/AMPLICOR HCV Monitor Test
  • Roche Diagnostics COBAS AmpliScreen HCV Test
  • Roche Diagnostics AMPLINAT MPX Test
  • Roche Diagnostics COBAS AMPLICOR HCV Test/AMPLICOR HCV Test
  
Human Immunodeficiency Virus (HIV)
Genetic probes for detection and quantification of HIV.

Buyer Products:

  • Roche Diagnostics COBAS AmpliScreen HIV-1 Test
  • Roche Diagnostics Amplicor HIV-1 Test
  • Roche Diagnostics AMPLINAT MPX Test
  
Human Papilloma Virus
Genetic probes for the detection of HPV.

Buyer Products:

  • Roche Diagnostics Digene Hybrid Capture II HPV Test
  
West Nile Virus
Genetic probe for detection and/or quantitation of West Nile Virus.

Buyer Products:

  • Roche Diagnostic TaqScreen West Nile Virus Test
  
Specimen Collection  
Blood  
Capillary  
Lancets
Sharps type of device used to puncture the skin in order to collect a capillary blood sample.

Buyer Products:

  • Roche Diagnostics Accu-Chek Autoclix Lancing System
  • Roche Diagnostics Safe-T-Pro Lancets
  • Roche Diagnostics Softclix Pro Lancets
  • Roche Diagnostics SoftTouch Lancets
  
Urinalysis  
Analyzers  
Chemistry
Analyzers used to perform chemical analysis of urine.

Buyer Products:

  • Roche Diagnostics Miditron M
  • Roche Diagnostics Urisys 2400
  • Roche Diagnostics Miditron Junior II
  • Roche Diagnostics Urisys 1100
  
Reagents  
Test Strips
Reagents, in a embedded strip format, used to perform chemical, and physical analysis of urine or body fluids.

Buyer Products:

  • Roche Diagnostics Chemstrip Series
  
Scientific Products  
Analytical Instruments  
Analyzers  
Gas Monitors  
Multiple Component  
Benchtop
Multi-component gas monitors that are generally located on the counter top.

Buyer Products:

  • Roche Diagnostics AVL OMNI 1-9
  
Bioanalytical Instruments  
Biomolecular  
Microplate Readers  
Systems  
Multiple Parameter
Microplate reader systems that used a combination of fluorescent, luminescent, and/or photoemission detectors.

Buyer Products:

  • Roche Diagnostics Lumi-Imager
  
Sequencers  
Automated  
Nucleic Acid
Automated gel electrophoresis or capillary electrophoresis sequencers used to analyze nucleic acid sample.

Buyer Products:

  • Genome Sequencer 20
  
Synthesizers  
Peptides
Synthesizer systems used for the identification and synthesis of peptide samples.

Buyer Products:

  • Roche Diagnostics Rapid Translation System
  
Thermal Cyclers  
Accessories
Supplementary products used to enhance the performance of a thermal cycler.

Buyer Products:

  • Roche Diagnostics MagNA Pure LC
  
Systems
Thermal cycler components assembled as a single unit.

Buyer Products:

  • Roche Diagnostics LightCycler
  
Consumables  
Bioanalytical Chemistry  
Molecular Biology  
Microarray Technology  
Microarray Chips
Microarray/biochip components that give detailed analysis of differential expression in normal and diseased or treated cells.

Buyer Products:

  • Roche Diagnostics AmpliChip CYP 450
  
Nucleic Acid Analysis  
Kits  
Nucleic Acid  
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA

Buyer Products:

  • Roche Diagnostics FuGENE
  
General Laboratory Equipment  
Automation Equipment  
Robotic Instruments  
Workstations
Robotic instrument systems that transfer liquid and gas samples and also heat and cool samples.

Buyer Products:

  • Roche Diagnostics Task Targeted Automation
  
Veterinary Products and Services  
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.

Target Products:

  • Protherics Enfer TSE Diagnostic Kit
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. n/a 197,233.738 18.27 13.50 4.17 4.14 9.26
Johnson & Johnson n/a 188,429.910 17.37 17.41 3.67 3.55 6.86
GlaxoSmithKline plc (ADR) n/a 157,749.428 16.17 15.59 3.62 3.73 17.12
Novartis AG (ADR) n/a 134,289.621 23.59 18.57 3.84 3.66 3.61
sanofi-aventis (ADR) n/a 127,378.760 27.87 13.44 3.35 3.53 -9.12
AstraZeneca PLC (ADR) n/a 98,768.323 18.17 16.47 3.97 3.83 9.59
Merck & Co., Inc. n/a 86,000.583 15.55 15.78 3.85 3.99 4.90
Amgen, Inc. n/a 78,791.131 29.28 18.23 5.95 5.53 47.35
Siemens AG (ADR) n/a 75,777.827 22.37 16.84 0.70 0.73 3.70
Abbott Laboratories n/a 74,862.543 24.11 19.57 3.39 3.36 44.96
Wyeth n/a 63,595.794 16.78 15.21 3.27 3.18 6.73
Eli Lilly & Co. n/a 62,205.854 19.81 17.82 4.13 4.08 5.21
Medtronic, Inc. n/a 52,617.609 20.92 18.86 4.66 4.17 15.27
Bristol Myers Squibb Co. n/a 42,555.965 14.91 18.05 2.20 2.22 8.77
Bayer AG (ADR) n/a 37,210.919 19.10 16.63 1.04 1.15 6.75
Schering-Plough Corporation n/a 29,715.339 40.38 27.85 2.98 2.90 4.00
Gilead Sciences, Inc. n/a 29,077.944 29.55 28.44 11.72 10.39 9.09
Schering AG (ADR) n/a 22,087.008 28.91 27.93 3.13 n/a 6.34
Genzyme Corporation n/a 17,966.979 38.88 30.53 6.07 5.64 6.87
Becton, Dickinson and Co. n/a 16,763.836 23.20 20.74 2.93 2.85 5.99
Celgene Corporation n/a 15,225.732 500.25 127.54 23.14 18.19 24.87
Biogen Idec Inc n/a 14,743.601 451.06 21.77 5.90 5.11 4.92
Serono S.A. (ADR) n/a 10,490.395 15.99 14.91 3.92 3.75 4.69
Shire plc (ADR) n/a 8,344.273 n/a 29.21 4.93 4.58 10.15
Altana AG (ADR) n/a 7,780.441 13.43 13.22 1.75 n/a 4.21

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Aspreva Pharmaceuticals Corporation 100.00% 802.212 7.95 7.03 4.55 3.53 3.59
Emisphere Technologies Inc. 80.40% 240.961 n/a -7.59 56.78 65.84 -8.53
deCODE genetics, Inc. 23.00% 298.548 n/a -3.83 6.70 6.86 -6.10
PDL BioPharma Inc. 3.30% 2,112.165 n/a -183.70 5.94 5.05 20.19
sanofi-aventis (ADR) n/a 127,378.760 27.87 13.44 3.35 3.53 -9.12
Genentech, Inc. n/a 86,373.982 52.80 44.02 11.03 9.68 13.41
Cardinal Health, Inc. n/a 28,155.662 28.60 18.49 0.35 0.32 8.05
Adobe Systems Incorporated n/a 19,732.632 33.41 32.08 8.62 7.69 9.71
Biogen Idec Inc n/a 14,743.601 451.06 21.77 5.90 5.11 4.92
Johnson Controls, Inc. n/a 14,647.849 15.28 14.82 0.48 0.46 39.38
Serono S.A. (ADR) n/a 10,490.395 15.99 14.91 3.92 3.75 4.69
Elan Corporation, plc (ADR) n/a 6,415.669 n/a -19.55 11.89 10.65 -9.44
Beckman Coulter, Inc. n/a 3,298.929 25.20 18.74 1.36 1.31 10.30
Atmel Corporation n/a 2,687.120 138.39 31.59 1.59 1.43 2.74
Sanmina-SCI Corporation n/a 1,864.912 n/a 12.54 0.17 0.17 3.07
Valeant Pharmaceuticals International n/a 1,766.630 n/a 52.03 2.04 2.02 -9.29
Nektar Therapeutics n/a 1,559.028 n/a -12.00 9.84 8.14 8.84
Crucell N.V. (ADR) n/a 928.684 n/a -25.64 19.44 5.61 5.42
Esterline Technologies Corporation n/a 896.273 16.66 16.89 1.01 0.93 16.24
Telik, Inc. n/a 879.005 n/a -8.65 n/a 2,284.68 5.42
Open Text Corporation (USA) n/a 769.893 423.98 15.66 1.86 1.83 9.42
ISIS Pharmaceuticals, Inc. n/a 509.376 n/a -9.09 16.21 12.26 75.88
Dendrite International, Inc. n/a 395.562 16.68 43.76 0.90 0.92 2.81
Enzo Biochem, Inc. n/a 387.318 n/a n/a 9.50 n/a 4.27
Target
  Symbion Health Limited n/a 1,495.227 24.73 n/a 0.51 n/a 5.19

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Applied Biosystems Group, Applera Corp n/a 5,869.805 21.85 23.97 3.07 2.85 n/a
IDEXX Laboratories, Inc. n/a 2,787.825 33.41 33.40 4.07 3.90 12.45
MDS Inc. (USA) n/a 2,702.598 73.14 n/a 2.04 n/a 5.05
Gen-Probe Incorporated n/a 2,581.549 41.75 45.01 7.69 7.36 5.48
PDL BioPharma Inc. n/a 2,112.165 n/a -183.70 5.94 5.05 20.19
Aspreva Pharmaceuticals Corporation n/a 802.212 7.95 7.03 4.55 3.53 3.59
Grupo Casa Saba, S.A. (ADR) n/a 570.652 8.04 n/a 0.27 n/a 1.33
Abaxis, Inc. n/a 474.810 53.11 41.73 6.33 n/a 6.31
Connetics Corporation n/a 347.862 14.01 -165.33 1.90 1.82 3.37
Enzon Pharmaceuticals, Inc. n/a 344.196 n/a 13.53 2.07 1.85 -3.03
Trimeris, Inc. n/a 212.624 n/a 96.90 17.79 6.23 9.36
IRIS International, Inc. n/a 152.475 23.34 24.39 2.35 n/a 2.76
Allion Healthcare, Inc. n/a 57.519 n/a 10.81 0.41 0.24 1.07

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Altana AG (ADR) n/a 7,780.441 13.43 13.22 1.75 n/a 4.21
Buyer
  GlaxoSmithKline plc (ADR) n/a 157,749.428 16.17 15.59 3.62 3.73 17.12
Novartis AG (ADR) n/a 134,289.621 23.59 18.57 3.84 3.66 3.61
sanofi-aventis (ADR) n/a 127,378.760 27.87 13.44 3.35 3.53 -9.12
Genentech, Inc. n/a 86,373.982 52.80 44.02 11.03 9.68 13.41
Amgen, Inc. n/a 78,791.131 29.28 18.23 5.95 5.53 47.35
Bayer AG (ADR) n/a 37,210.919 19.10 16.63 1.04 1.15 6.75
Gilead Sciences, Inc. n/a 29,077.944 29.55 28.44 11.72 10.39 9.09
Allergan, Inc. n/a 16,976.578 n/a 30.86 6.46 5.67 -744.59
Biogen Idec Inc n/a 14,743.601 451.06 21.77 5.90 5.11 4.92
Serono S.A. (ADR) n/a 10,490.395 15.99 14.91 3.92 3.75 4.69
Laboratory Corp. of America n/a 8,521.112 21.42 21.25 2.46 2.38 -96.83
Altana AG (ADR) n/a 7,780.441 13.43 13.22 1.75 n/a 4.21
Elan Corporation, plc (ADR) n/a 6,415.669 n/a -19.55 11.89 10.65 -9.44
Applied Biosystems Group, Applera Corp n/a 5,869.805 21.85 23.97 3.07 2.85 n/a
IDEXX Laboratories, Inc. n/a 2,787.825 33.41 33.40 4.07 3.90 12.45
MDS Inc. (USA) n/a 2,702.598 73.14 n/a 2.04 n/a 5.05
Gen-Probe Incorporated n/a 2,581.549 41.75 45.01 7.69 7.36 5.48
Target
  AstraZeneca PLC (ADR) n/a 98,768.323 18.17 16.47 3.97 3.83 9.59
Altana AG (ADR) n/a 7,780.441 13.43 13.22 1.75 n/a 4.21
Symbion Health Limited n/a 1,495.227 24.73 n/a 0.51 n/a 5.19
Beacon Pharmaceuticals Ltd. n/a n/a n/a n/a n/a n/a n/a
Cancer Research UK n/a n/a n/a n/a n/a n/a n/a
Enfer Scientific Ltd. n/a n/a n/a n/a n/a n/a n/a
Swedish Orphan AB n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 27,655.5 33.3 27,688.8
Other Revenue 0.0 0.0 0.0
Total Revenue 27,655.5 33.3 27,688.8
Cost of Revenue 7,245.8 21.2 7,267.0
SG&A Expense 9,277.7 17.3 9,295.0
Depreciation & Amortization 787.4 0.0 787.4
Research & Development 4,443.0 12.7 4,455.7
Interest Expense 0.0 0.0 0.0
Other Operating Expense -1,126.9 0.0 -1,126.9
Unusual Expense (Income) 277.2 0.0 277.2
Total Expenses 20,904.2 51.2 20,955.4
Operating Income 6,751.3 -17.9 6,733.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 231.3 -0.1 231.2
Other, Net 0.0 0.0 0.0
Income Before Taxes 6,982.6 -18.0 6,964.6
Income Taxes 1,732.0 -0.1 1,731.9
Income After Taxes 5,250.6 -17.8 5,232.7
Minority Interest (IS) -734.4 0.0 -734.4
Net Income - Excl. Xord. Items 4,516.2 -17.8 4,498.3
Discontinued Operations -9.3 0.0 -9.3
Net Income - Incl. Xord. Items 4,506.8 -17.8 4,489.0
Income Avail. to Common 4,506.8 -17.8 4,489.0
Share Items
Basic Avg. Shares Outstanding 1,690.0 25.1 1,715.1
Basic EPS - Excl. Xord. Items 5.34 n/a 2.62
Basic EPS - Incl. Xord. Items 2.67 n/a 2.62
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 1,720.0 25.1 1,745.1
F.D. EPS - Excl. Xord. Items 2.63 n/a 2.58
F.D. EPS - Incl. Xord. Items 2.62 n/a 2.57
Dividends Per Common Share 0.97 0.00 0.97
Balance Sheet
Assets
Cash and Equivalents 3,292.7 47.8 3,340.5
ST Investments 12,972.2 0.0 12,972.2
Accounts Receivable 5,995.1 9.8 6,004.9
Inventory 3,925.9 20.5 3,946.3
Other Current Assets 1,559.1 0.0 1,559.1
Current Assets 27,745.0 78.1 27,823.1
Accum D&A 0.0 0.0 0.0
PPE, Net 11,757.3 15.2 11,772.6
Goodwill & Intangibles 9,647.6 19.3 9,666.9
Long Term Investments 1,750.7 0.0 1,750.7
Other Assets 0.0 0.0 0.0
Other LT Assets 3,119.8 0.4 3,120.2
Total Assets 54,020.5 113.0 54,133.5
Liabilities
Accounts Payable 1,848.1 29.6 1,877.6
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 3,992.8 0.0 3,992.8
ST Debt 0.0 0.1 0.1
Curr Port of LTD & Cap Lease Oblg 271.0 1.2 272.2
Other (Current) Liabilities 1,280.3 0.8 1,281.1
Current Liab. 7,392.2 31.6 7,423.8
LT Debt 7,259.8 5.1 7,264.9
Capitalized Lease Obligations 0.0 2.3 2.3
Total LT Debt 7,259.8 7.3 7,267.2
Minority Interest (BS) 5,312.1 0.0 5,312.1
Deferred Taxes 2,739.8 0.0 2,739.8
Other LT Liab. 4,119.8 24.6 4,144.4
Total Liabilities 26,823.7 63.5 26,887.2
Shareholders Equity
Common Stock 124.6 9.7 134.4
Additional Paid in Capital 0.0 163.1 163.1
Retained Earnings 29,786.2 -122.9 29,663.3
Treasure Stock -2,714.1 0.0 -2,714.1
Other Equity 0.0 -0.4 -0.4
Total Equity 27,196.8 49.5 27,246.3
Total Liab. & Equity 54,020.5 113.0 54,133.5
Shares Outstanding 1,725.1 25.9 1,751.1
Cash Flow
Operating Cash Flow
CF Net Income 0.0 -17.9 -17.9
CF Depreciation 0.0 2.6 2.6
CF Amortization 0.0 0.2 0.2
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items -411.2 1.6 -409.6
Change in Working Capital 5,142.3 37.1 5,179.4
Total Cash From Operating Activities 4,731.1 23.6 4,754.7
Investing Cash Flow (not calculated)
Capital Expenditures -1,464.9 -3.7 -1,468.6
Other Investing Cash Flows -2,600.4 1.3 -2,599.0
Total Cash From Investing Activities -4,065.3 -2.4 -4,067.7
Financing Cash Flow (not calculated)
Dividends Paid -1,393.2 0.0 -1,393.2
Purchase Or Sale of Stock -1,575.5 15.1 -1,560.4
Purchase and Retirement of Debt -735.2 -1.1 -736.3
Other Financing Cash Flow 1,221.1 -0.7 1,220.4
Total Cash From Financing Activities -72.4 13.0 -59.4
Exchange Rate Effects -68.5 0.0 -68.5
Net Change in Cash 524.9 34.2 559.1
Cash Taxes Paid 603.6 0.1 603.7
Cash Interest Paid 151.1 0.7 151.8